Advisors Preferred’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.44M Buy
+381,183
New +$9.08M 1.39% 19
2025
Q1
Sell
-50,171
Closed -$1.08M 261
2024
Q4
$1.08M Buy
+50,171
New +$1.08M 0.17% 71

Other funds holding CPRX

Advisors Preferred's CPRX Position: Q1 2026 in Review

Advisors Preferred opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 381,183 shares worth $9.44M. The stake represents 1.39% of the portfolio and ranks #19 among its holdings. This is a return to the name: Advisors Preferred previously reported a position in CPRX as recently as Q4 2024.

Advisors Preferred first reported a position in CPRX in Q4 2024 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Advisors Preferred held 381,183 shares of Catalyst Pharmaceutical worth $9.44M as of Q1 2026.
  • Catalyst Pharmaceutical was a new Advisors Preferred position in Q1 2026.
  • Catalyst Pharmaceutical made up 1.39% of Advisors Preferred's portfolio in Q1 2026, its #19 holding.
  • Advisors Preferred first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Advisors Preferred's 13F filing for Q1 2026, filed 5 May 2026.